Drug Profile
Metformin/sulfonylurea - Assertio Therapeutics
Alternative Names: Metformin GR/sulfonylureaLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Depomed
- Developer Assertio Therapeutics
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 31 Dec 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 09 Feb 2004 Preclinical trials in Type-2 diabetes mellitus in USA (PO)